This newest software delivers improved image quality across Swoop system sequences, a more intuitive scanning experience, and new foundational isotropic imaging designed to strengthen the clinical utility...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the...
Recent publications in the prominent Journal of Neurosurgery and Stroke provide new evidence supporting the clinical value of the Swoop system in stroke care and neurosurgical settings.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop®...
Hyperfine has initiated the launch of the next-generation Swoop® system in European markets, beginning the global expansion of its most advanced portable MRI technology.
Leading neurosurgeons from around the world will help guide the role of the Swoop® system in neurosurgical care, including surgical workflow, product capabilities, and clinical evidence.
Routine clinical use is accelerating, driven by advanced image quality, expanding clinical utility, and increasingly diverse use cases across hospital and office settings.
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop®...
Prospective randomized ED study shows rapid bedside imaging, detection of critical neurological findings, and potential workflow efficiency benefits with portable MRI
Hyperfine (NASDAQ:HYPR) reported a sharp year-over-year increase in first-quarter revenue and reiterated its full-year 2026 outlook, as management pointed to continued adoption of its next-generation Swoop...